Hypersensitivity to the active substance or to any of the excipients of this medicinal product; Pregnancy; Severe renal failure and patients undergoing haemodialysis; Severe hepatic insufficiency; Severe gastrointestinal disorders; Stomach ulcer; Heart disorders; Haematological disorders, such as blood dyscrasias; During the 14 days subsequent to the use of CYP3A4 and/or P glycoprotein inhibitors.